glp-1 receptor agonists benefits in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies The expanding role of GLP-1

Nature in November 2023

The addition of insulin, which usually acts as a vasodilatory agent, did not increase MBV or MBF compared with GLP-1 alone, which suggests the presence of microvascular insulin resistance and the insulin-independent effects of GLP-1 on cardiac microvasculature

Semaglutide and liraglutide are injectable GLP-1 receptor agonists that target these incretin receptors to take advantage of the latter effects to promote weight loss

Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM et al (2013) Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study